↓ Skip to main content

Dove Medical Press

Article Metrics

Critical appraisal of bevacizumab in the treatment of ovarian cancer

Overview of attention for article published in Drug Design, Development and Therapy, April 2015
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
24 Dimensions

Readers on

mendeley
31 Mendeley
Title
Critical appraisal of bevacizumab in the treatment of ovarian cancer
Published in
Drug Design, Development and Therapy, April 2015
DOI 10.2147/dddt.s83275
Pubmed ID
Authors

Hiroyuki Yoshida, Akira Yabuno, Keiichi Fujiwara

Abstract

Bevacizumab is the first molecular-targeted agent to be used for the treatment of ovarian cancer. Bevacizumab is a humanized monoclonal antibody targeting vascular endothelial growth factor. Two randomized Phase III trials evaluated the combination of bevacizumab plus standard cytotoxic chemotherapy for first-line treatment of advanced ovarian cancer. Additional Phase III trials evaluated bevacizumab combined with cytotoxic chemotherapy in platinum-sensitive and platinum-resistant recurrent ovarian cancer. All these trials reported a statistically significant improvement in progression-free survival but not in overall survival. Furthermore, bevacizumab effectively improved the quality of life with regard to abdominal symptoms in recurrent ovarian cancer patients. Bevacizumab is associated with adverse events not commonly observed with cytotoxic agents used to treat gynecological cancers, such as hypertension, bleeding, thromboembolism, proteinuria, delayed wound healing, and gastrointestinal events. However, most of these events can be adequately managed by gynecologists. The clinical trial results with bevacizumab have supported its recent approval in Europe and the United States as a treatment for ovarian cancer. This review presents the latest evidence for bevacizumab therapy of ovarian cancer and describes selection of patients for personalized treatment.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 31 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 6 19%
Researcher 5 16%
Student > Master 3 10%
Student > Doctoral Student 2 6%
Student > Ph. D. Student 2 6%
Other 5 16%
Unknown 8 26%
Readers by discipline Count As %
Medicine and Dentistry 7 23%
Biochemistry, Genetics and Molecular Biology 3 10%
Economics, Econometrics and Finance 3 10%
Engineering 2 6%
Nursing and Health Professions 2 6%
Other 4 13%
Unknown 10 32%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 May 2015.
All research outputs
#9,084,876
of 11,348,501 outputs
Outputs from Drug Design, Development and Therapy
#677
of 1,186 outputs
Outputs of similar age
#160,552
of 225,994 outputs
Outputs of similar age from Drug Design, Development and Therapy
#45
of 78 outputs
Altmetric has tracked 11,348,501 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,186 research outputs from this source. They receive a mean Attention Score of 3.8. This one is in the 29th percentile – i.e., 29% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 225,994 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 78 others from the same source and published within six weeks on either side of this one. This one is in the 30th percentile – i.e., 30% of its contemporaries scored the same or lower than it.